Lupus ACR 2023 Brochure LF

ACR 2023 

Congress Preview 

Chair’s Introduction 

Dear Colleagues, 

Welcome to the Lupus Forum ACR 2023 Highlights Brochure, providing you with all you need to know about the lupus 

content at this year’s Convergence, including the Scientific Sessions, Posters, Abstracts, and Industry Symposiums. 

I’ve selected my Chair’s picks of the key content – I hope you find them useful. 

There’s plenty of great lupus content on Sunday, including the poster session, SLE – Treatment Poster I. In this session we 

see the reporting of post-hoc analyses of treatment responses by SF-36 in the anifrolumab Phase 3 long-term extension 

trial (0582), and the impact of belimumab on steroid use and disease activity from OBSErve (0587). Also within this session 

is a poster comparing IgA2 anti-dsDNA antibodies and clinical outcome in trials of belimumab after rituximab (0589), 

further data from the investigation into CAR T cell therapy in SLE (0607), and data on the efficacy of cenerimod in patients 

with high IFN-1 gene expression signature (0608). We then have three posters from Lupus Forum Steering Committee 

member, Richard Furie, on renal involvement in anifrolumab-treated SLE patients (0595), SRI-4 and BICLA responses from 

the Phase 2 trial of deucravacitinib (0596), and efficacy of anifrolumab assessed by improvements in SLEDAI-2K (0597). 

One final pick on Sunday comes in the Abstract Session, SLE – Treatment I: Renal, a post-hoc analysis of the Phase 2 

trial of lupus nephritis patients treated with obinutuzumab (0784). 

On Monday I would draw your attention to Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease, 

and a poster on belimumab safety in paediatric patients (1257) offering new data for this patient group. SLE – Treatment 

Poster II sees data on the year 5 follow up of belimumab safety (1499) and LLDAS achievement in patients receiving 

deucravacitinib (1501). 

Tuesday features my last three Chair’s picks. SLE – Treatment Poster III includes post-hoc analysis of belimumab efficacy 

by race and ethnicity (2347), while the abstract session, SLE – Treatment II: Nonrenal sees Phase 2 data on emerging 

treatments, ianalumab in SLE (2487), and CLASI achievement with deucravacitinib in patients with CLE (2489). 

We add new content to the Lupus Forum regularly, with monthly summaries of key publications, podcasts, and congress 

materials such as these. You can register for updates at lupus-forum.com or keep up to date by following us on Twitter 

@LupusForum and on LinkedIn by searching “Lupus Forum”. 

I hope you find our selection of highlights useful and that you enjoy the meeting in San Diego! 

Ed Vital 

Chair of the Lupus Forum Steering Committee; Associate Professor, University of Leeds 

Developed under 

the auspices of 

Supported with educational grants from 

Sponsorship 

received from

Key: CP Chair’s pick Abstract session Poster session 

Scientific session 

Key Lupus Content 

Sunday, 12 November 2023 

09:00– 

10:00 

09:00– 

10:00 

09:00– 

11:00 

0006 

09:00– 

11:00 

0014 

09:00– 

11:00 

0178 

09:00– 

11:00 

0543 

0560 

09:00– 

11:00 

0582 

Lupus Prevention and Disease-Modifying 

Anti-Lupus Drugs (DMALDs), Are We There Yet? 

Anca Askanase, Maria Dall’Era, David Karp 

Under Pressure: Updates in Lupus Nephritis 

Simone Appenzeller, Hermine Brunner, 

Mark Mitsnefes 

B Cell Biology & Targets in Autoimmune 

& Inflammatory Disease Poster 

Preclinical Characterization of a Novel anti-CD40 

Antagonist Antibody-glucocorticoid Conjugate 

with Superior Preclinical Efficacy and Favorable 

Safety Profile 

Wenming Ren 

Genetics, Genomics & Proteomics Poster 

The 330 Genetic Risk Loci of Systemic Lupus 

Erythematosus (SLE) Now Known Are Consonant 

with Multiple Causal Mechanisms Involving 

Epstein-Barr Virus (EBV)-Encoded Transcription 

Co-factors (TFs) in EBV-Infected B Cells 

Viktoryia Laurynenka 

Healthcare Disparities in Rheumatology 

Poster 1: Lupus 

Traditional and Lupus-Specific Risk Factors 

for Cardiovascular Events Among Patients with 

Systemic Lupus Erythematosus 

Saloni Patolia 

SLE – Diagnosis, Manifestations, 

& Outcomes Poster I 

Sensitivity of the 2019 European Alliance of 

Associations for Rheumatology/American College 

of Rheumatology Classification Criteria for 

Systemic Lupus Erythematosus in a Populationbased 

Cohort; A Study Set in Norway 2000–2015 

Hilde Haukeland 

Genetic Determinants of Lupus Nephritis and 

Kidney Function in Systemic Lupus Erythematosus 

Linda Hiraki 

SLE – Treatment Poster I 

Evaluation of Anifrolumab Treatment 

Responses by the Short Form 36 Health 

Survey Version 2 in SLE: A Post Hoc 

Analysis of the Placebo-Controlled Phase 3 

Long-Term Extension Trial 

Vibeke Strand 

CP 

0583 

0584 

0587 

0588 

0589 

0590 

0591 

0592 

0593 

0594 

0595 

Therapeutic Potential of Imvotamab, a 

CD20-Targeted Bispecific IgM T Cell Engager, 

for the Treatment of Refractory Autoimmune 

Disease Patients 

Racquel Domingo-Gonzalez 

Targeting Key Components of SLE Pathogenesis 

with the Multifaceted Immunomodulatory 

Properties of Cenerimod, a Selective S1P1 

Receptor Modulator 

Marianne Martinic 

Impact of up to 24 Months Intravenous (IV) CP 

Belimumab (BEL) Treatment on Steroid Use 

and Disease Activity in Patients with SLE in 

Clinical Practice: Additional Post Hoc Pooled 

Analysis of Multicountry OBSErve Cohort Data 

Roger A Levy 

Long Term Safety and Predictors of Serious 

Infections Among Patients with Systemic Lupus 

Erythematosus Treated with Rituximab: Audit from 

a Single Center Biologic Registry 

Augustine Jose 

A Comparative Evaluation of IgA2 

Anti-dsDNA Antibodies and Clinical 

Outcome in Two Clinical Trials of Belimumab 

After Rituximab in SLE 

Muhammad RA Shipa 

Comparing Safety and Efficacy of Sodium-Glucose 

Co-Transporter 2 Inhibitors versus Dipeptidyl 

Peptidase 4 Inhibitors in Patients with Systemic 

Lupus Erythematosus and Comorbid Type 2 

Diabetes Mellitus 

Jui-En Lo 

Despite Dramatic Expansion of Approved Biologics 

in SLE, Unmet Needs Remain 

Ryan Rex 

Real-World Treatment Patterns in Patients with 

Systemic Lupus Erythematosus: An Analysis of 

the SLE Prospective Observational Cohort Study 

(SPOCS) 

Martin Aringer 

Lupus Nephritis of the Spanish National Registry 

of Belimumab in Patients with Systemic Lupus 

Erythematosus 

Vicente Aldasoro 

Baseline Innate Immunity Transcriptional 

Signatures Act as Predictors of Response to 

Immunosuppressive and Biologic Treatments in 

Systemic Lupus Erythematosus While Disturbances 

Linked to p53-signaling Define “Resistant” Disease 

Panagiotis Garantziotis 

Renal Involvement in Patients with 

Systemic Lupus Erythematosus Treated 

with Anifrolumab Compared with Placebo 

over a 4-Year Period 

Richard A Furie 

CP 

CP



0596 

0597 

0598 

0599 

Deucravacitinib, an Oral, Selective, 

CP 

Allosteric Tyrosine Kinase 2 Inhibitor, in a 

Phase 2 Trial in Systemic Lupus Erythematosus 

(SLE): Achievement of Sustained SRI(4), 

BICLA and Dual Responses over 48 Weeks 


Efficacy of Anifrolumab in Systemic 

CP 

Lupus Erythematosus by Overall and 

Organ-Specific SLEDAI-2K Improvements: 

Results from the Randomized, Placebo- 

Controlled Phase 3 Long-Term Extension Study 


Litifilimab Modulates Type I IFN Biomarkers 

in Patients with SLE or CLE in the Phase 2 

LILAC Study 


Targeted Inhibition of Cathepsins Limits the 

Intracellular Complement Activation in Lupus 

Nephritis Podocytes 

Ana Kunzler 

0782 

0784 

16:00– 

17:30 

0847 

Comparison of Dual-immunosuppressive 

Therapy with a Voclosporin-based, Tripleimmunosuppressive 

Regimen for Lupus Nephritis 

in the ALMS and AURORA 1 Studies 

Maria Dall’Era 

Kidney-Related Outcomes and Steroid- 

Sparing Effects in Patients with Active 

Lupus Nephritis Treated with Obinutuzumab: 

A Post Hoc Analysis of a Phase 2 Trial 

Brad Rovin 


& Outcomes I: Biomarkers 

Development of an IFN 5-Gene Signature Score 

to Identify IFN-high and IFN-low Subsets and as a 

Pharmacodynamic Biomarker for Deucravacitinib 

Treatment in a Phase 2 Trial in Patients with 


Chun Wu 

CP 

0600 

0604 

0606 

0607 

0608 

12:00– 

13:00 

14:00– 

15:30 

0781 

Identification of Subsets of SLE Patients 

Responsive to Baricitinib by Transcriptomic 

Analysis at Baseline 

Prathyusha Bachali 

Is Belimumab Dose Optimization Possible in 

Patients with Systemic Lupus Erythematosus?: 

Analysis of This Therapeutic Strategy in a Large 

Multicenter Cohort of Patients from Spanish 

Rheumatology Departments 

Irene Altabas Gonzalez 

Risk of Damage Progression with Belimumab 

versus Oral Immunosuppressant Use in Patients 

with Systemic Lupus Erythematosus 

April Jorge 

CAR T Cell Therapy Leads to Long-term 

Abrogation of Autoimmunity in SLE 

Patients While Vaccination Responses 

Are Maintained 

Georg Schett 

Efficacy of Cenerimod in Patients with 

High IFN-1 Gene Expression Signature and 

High Anti-dsDNA Antibody Levels: Post-hoc 

Analysis from a Phase 2 Study 

Anca Askanase 

Interventions to Increase Minority Participation in 

Lupus Clinical Trials 

Irene Blanco, Saira Sheikh 

SLE – Treatment I: Renal 

Low vs. High Initial Oral Glucocorticoid Dose for 

Lupus Nephritis Induction Treatment: A Pooled 

Analysis of Randomized Controlled Clinical Trials 

Amit Saxena 

CP 

CP 

Monday, 13 November 2023 

07:30– 

08:30 

09:00– 

11:00 

0928 

09:00– 

11:00 

1227 

1247 

09:00– 

11:00 

1489 

1490 

Meet the Panel: The Latest in Lupus Treatment 

Maria Dall’Era, Richard A Furie, Marta Mosca 

SLE – Etiology & Pathogenesis Poster 

Skewing of B Cell Receptor Repertoire in 

Unswitched Memory B Cells Is Associated with 

Disease Activity of Systemic Lupus Erythematosus 

and Targeted by Belimumab 

Keishi Fujio 

Pediatric Rheumatology – Clinical Poster II: 

Connective Tissue Disease 

Serious Infections Following Rituximab 

Administration in Children with Systemic 

Lupus Erythematosus 

Jordan Roberts 

Pharmacokinetic, Pharmacodynamic, and 

Safety Profile of Subcutaneous Belimumab 

in Pediatric Patients with Systemic Lupus 

Erythematosus: Analysis of Data from a 

Multicenter, Open-Label Trial 

Hermine Brunner 

SLE – Treatment Poster II 

Treatment with Upadacitinib in Patients with 

Systemic Lupus Erythematosus Results in the 

Inhibition of B-Cell–related Biomarkers: Analysis 

of the M19-130 (SLEek) Phase 2 Study 

Marie-Claude Gaudreau 

Early Experience with SGLT2i in Systemic 

Lupus Erythematosus 

Michelle Petri 

CP



1492 

1493 

1494 

1495 

1496 

1498 

1499 

1500 

Pre-treatment Differentially Expressed 

Metagenes Characterize Systemic Lupus 

Patients Who Subsequently Achieve Clinical 

Response to Belimumab 

Miles Smith 

Novel BCMA-CD19 Compound CAR-T (cCAR) 

Targets B Cells and Plasma Cells Achieving 

Immune Reset and Eliminates All Autoantibodies 

in Systemic Lupus Erythematosus (SLE) and Lupus 

Nephritis (LN) Patients Resulting in Long-Term, 

Medication-Free Remission 

Greg Deener 

The Effect of Belimumab on Steroid Use in 

Patients with SLE: Results from a Retrospective 

Observational Study of Real-World Data from a 

US Rheumatology Provider Network 

Karen Worley 

Deep Serological Profiling of SLE Patients Treated 

with anti-CD19 CAR T Cells 

Samik Basu 

Clinical Safety and Efficacy Results from 

EQUALISE Type B: A Phase 1b Open-label Clinical 

Study of Itolizumab, a Novel anti-CD6 Therapy, in 

Subjects with Active Proliferative Lupus Nephritis 

Kenneth Kalunian 

First-in-Human Safety, Tolerability, 

Pharmacokinetics, and Pharmacodynamics 

Study of DS-7011a, an Anti-TLR7 Antagonistic 

Monoclonal Antibody for the Treatment of 


Giorgio Senaldi 

Year-5 Follow-up of Belimumab Safety CP 

(Mortality and Malignancies) in Patients with 

Systemic Lupus Erythematosus (SLE) Who 

Completed a Phase 4, 52-week, Randomized, 

Double-blind Placebo-controlled Safety Study 

Saira Sheikh 

Cumulative Infections by Week 52 Among 

Patients with SLE: A Summary of Data from 

Placebo-Controlled Belimumab Studies 

Saira Sheikh 

1504 

1505 

1507 

1508 

1511 

1512 

14:00– 

15:00 

16:00– 

17:30 

1694 

1696 

Characteristics and Prior Treatment Journey of 

Systemic Lupus Erythematosus (SLE) Patients 

Who Were Prescribed Anifrolumab – Observations 

from the American Rheumatology Network (ARN) 

in the U.S 

Vasileios Kyttaris 

Long-term Safety and Efficacy of Voclosporin in 

Black Patients with Lupus Nephritis: Results from 

the AURORA 1 and AURORA 2 Studies 

Gabriel Contreras 

Pharmacodynamic Changes in SLE Relevant Gene 

Expression Induced by Deucravacitinib in Patients 

Enrolled in the Phase 2 PAISLEY Trial 

Yanhua Hu 

Predicting in Virtual Patients the Efficacy of an 

Anti IFNa Mab in Cutaneous Lupus Erythematosus 

Philippe Moingeon 

B-Cell Recovery in a Randomized Controlled Trial 

of B-Cell Depletion with Obinutuzumab for the 

Treatment of Proliferative Lupus Nephritis 

Ed Vital 

Rituximab Objective Outcome Measures Trial in 

SLE (ROOTS): Randomised and Rescue Therapy 

Outcomes from a Randomised Controlled Trial 

Ed Vital 

Cutting Through the Brain Fog: Cognitive 

Dysfunction in Lupus 

Ian Bruce, Carla Cuda, Meggan Mackay 


& Outcomes II: Omics 

Transcriptomic Analysis of the Impact of 

Iberdomide on Patients with SLE 

Peter Lipsky 

Multi-Omic Profiling Reveals Immune Cell 

Priming Signature Linked to Systemic Lupus 

Erythematosus Prognosis 

Sarfaraz Hasni 

1501 

Lupus Low Disease Activity State (LLDAS) CP 

Achievement with Deucravacitinib, an Oral, 

Selective, Allosteric Tyrosine Kinase 2 Inhibitor, 

in a Phase 2 Trial in SLE 

Eric Morand 

1502 

Introduction of Belimumab Within Five Years of 

the Onset of Systemic Lupus Erythematosus (SLE) 

Contributes to the Better Therapeutic Response; 

A Multi-center Retrospective Cohort Study 

Kanako Kojima 

1503 

Disease Course and Complement as Predictors 

of Response to Standard of Care Plus Placebo 

in Patients with SLE: A Post Hoc Analysis of 

Dapirolizumab Pegol and Epratuzumab Clinical 

Trial Data 

Joan Merrill



Tuesday, 14 November 2023 

09:00– 

10:00 

Lupus in Africa 

Ida Dey, Hakeem Olaosebikan, Kate Webb 

2333 

Dapirolizumab Pegol Impacts Important 

Immunologic Pathways in SLE: Pharmacodynamic 

Analysis of B Cell and Type I Interferon Pathways 

from a Phase 2b Trial 

Ioana Cutcutache 

09:00- 

11:00 

2024 

09:00– 

11:00 

2264 

2277 

Patient Outcomes, Preferences, 

& Attitudes Poster III 

Patient-Reported Outcomes in Patients with Lupus 

Nephritis: A Post Hoc Analysis of Control Arm 

Data from Two Completed Phase III Randomized 

Clinical Trials 

Lisa Lindsay 


& Outcomes Poster III 

Proposal for Defining Moderate and Severe 

Activity States in Systemic Lupus Erythematosus. 

Impact on Flares and Other Outcomes 

Ivonne Lourdes Mamani Velarde 

Patients with Systemic Lupus Erythematosus: 

A Comparative Study Between Two Large, 

Multi-centric, Spanish and Argentinian Registers, 

Focused on Outcomes Differences 

Iñigo Rúa-Figueroa 

2334 

2336 

2337 

2338 

Remission Attainment in Patients with Systemic 

Lupus Erythematosus Treated with Anifrolumab 

Compared with Placebo over a 4-Year Period 

Ronald van Vollenhoven 

Identification of Urine Metabolites Linked 

to Disease Activity That Are Modulated by 

Anifrolumab in a Phase 2 LN Trial Using 

Untargeted Metabolomics Analysis 

David Jayne 

Safety and Tolerability of NIM-1324, an Oral, 

Once-daily LANCL2 Agonist, in a Randomized, 

Double-Blind, Placebo-Controlled Phase 1 Study 

in Normal Healthy Volunteers 

Andrew Leber 

Results of Single-Arm, Phase 1b Study of 

Anti-C1q Treatment (ANX009) Show That the 

Classical Pathway Is a Key Driver of Complement 

Activation and Consumption in Patients with 

Active Lupus Nephritis 

Maria Dall’Era 

2296 

2297 

2306 

Association Between EQ-5D-5L and SLEDAI 

Scores in Patients with Systemic Lupus 

Erythematosus in the United States and Europe: 

A Real-world Survey 

Ebuwa Igho-Osagie 

Interferon-α as a Biomarker to Predict Flares in 

Lupus Nephritis 

Laura Patricia Whittall Garcia 

Changes in Rheumatology Disease Measures 

After Initiation of Belimumab Treatment in Patients 

with Systemic Lupus Erythematosus 

Bernard Rubin 

2341 

2342 

2344 

Spanish National Registry of Belimumab in 

Patients with Systemic Lupus Erythematosus 

Vicente Aldasoro 

Modulation of B Cell and Interferon Pathways 

by Ianalumab in Patients with Systemic Lupus 

Erythematosus: Findings from a Phase 2 Clinical Trial 

Thomas Dörner 

Telitacicept versus Belimumab for Patients 

with Active Systemic Lupus Erythematosus: 

A Retrospective, Multicenter, Real-world 

Observational Study 

Huizhi Jin 

09:00– 

11:00 

2326 

2328 

2331 

2332 

SLE – Treatment Poster III 

Efficacy and Safety of Voclosporin in Patients 

with Proteinuria > 2 G/g 

Emily Littlejohn 

Deucravacitinib, an Oral, Allosteric, Tyrosine 

Kinase 2 (TYK2) Inhibitor, in Patients with Active 

Systemic Lupus Erythematosus: Patient-Reported 

Outcomes in a Phase 2 Trial 

Marta Mosca 

Molecular Predictors of Treatment Response 

in Two Trials of Abatacept in Systemic Lupus 

Erythematosus 

Kevin Thomas 

Dapirolizumab Pegol Efficacy by Subgroups in 

Patients with SLE: A Post Hoc Analysis of Phase 

2b Clinical Trial Data 

Anca Askanase 

2345 

2346 

2347 

2348 

Paired Kidney Biopsies from the AURORA 2 Study 

of Voclosporin in Active Lupus Nephritis 

Samir Parikh 

SLE Medication Usage and Organ Damage 

Among Adult SLE Patients with SLE Treated 

with Belimumab (BEL): Pooled Data from Three 

Open-Label Extension Studies over 11+ Years 

Zahi Touma 

Efficacy of Belimumab in Patients with 

Systemic Lupus Erythematosus by Race 

and Ethnicity: A Large Post Hoc Integrated 

Analysis of Five Clinical Trials 

Saira Sheikh 

Incidence of Infections Among Adult Patients 

with SLE Treated with Belimumab (BEL): 

Pooled Data from Three Open-Label Extension 

Studies over 11+ Years 

Jinoos Yazdany 

CP



2349 

2350 

2351 

11:00– 

12:00 

14:00– 

15:30 

2485 

2487 

2488 

2489 

2490 

Selection of the Dose for Subcutaneous 

Administration to Non-Japanese Subjects and 

Intravenous Administration to Japanese Subjects 

in the First-in-Human Study of DS-7011a, an 

Anti-TLR7 Monoclonal Antibody for the Treatment 

of Systemic Lupus Erythematosus 

Li Zhang 

Upregulation of Both APRIL and BAFF in Systemic 

Lupus Erythematosus Suggests Non-Redundant 

Roles, Further Revealed by Dual Inhibition with 

Povetacicept (ALPN-303; TACI vTD-Fc) 

Tiffany Blair 

Health Outcomes Among Patients (Pts) with SLE 

Initiating Belimumab (BEL) With and Without the 

Use of Immunosuppressants in the Previous 2 Years 

Karen Worley 

Advancing Non-Invasive Biomarkers in 

ANCA-Associated Vasculitis and Lupus Nephritis: 

A Translational State of the Art 

Salem Almaani, Andrea Fava, Brad Rovin 

SLE – Treatment II: Nonrenal 

Comparative Risk of Serious Psychiatric Events 

with Belimumab versus Oral Immunosuppressant 

Use in Patients with Systemic Lupus Erythematosus 

April Jorge 

Phase 2 Safety and Efficacy of Subcutaneous 

(s.c.) Dose Ianalumab (VAY736; Anti-BAFFR 

mAb) Administered Monthly over 28 Weeks in 

Patients with Systemic Lupus Erythematosus 

(SLE) of Moderate-to-Severe Activity 

Nan Shen 

Efficacy and Safety of ABBV-599 High Dose 

(Elsubrutinib 60 mg and Upadacitinib 30 mg) 

and Upadacitinib Monotherapy for the Treatment 

of Systemic Lupus Erythematosus: A Phase 2, 

Double-blind, Placebo-controlled Trial 

Joan Merrill 

Cutaneous Lupus Erythematosus Disease CP 

Area and Severity Index (CLASI) Achievement 

and Sustained Response with Deucravacitinib, 

an Oral, Selective, Allosteric Tyrosine Kinase 2 

Inhibitor, in a Phase 2 Trial in SLE 

Cristina Arriens 

Safety and Efficacy of Mycophenolate Mofetil 

in New-onset Systemic Lupus Erythematosus 

with High Titer of Anti-dsDNA Antibody and 

Without Major Organ Involvement: A Multicenter 

Randomized Controlled Trial 

Junna Ye 

CP 

14:00– 

15:00 

16:00– 

17:00 

16:00– 

17:30 

2551 

TeleRheumatology Research: Where We Are Today? 

Jeffrey Curtis, Leila Khalili, Daniel Solomon 

Personalized Nutrition for Patients with 

Rheumatic Diseases 

Danica Cowan, Hana Kahleova, Sarah Patterson 


& Outcomes III: Disease Activity 

Remission and Low Disease Activity (LDA) in 

Patients with SLE Treated with Belimumab (BEL): 

Results from a Large Integrated Analysis 

Ioannis Parodis 

Wednesday, 15 November 2023 

08:00– 

09:00 

Heterogeneity in Lupus: Lessons from the 

Autoimmunity Centers of Excellence 

Marcus Clark, Virginia Pascual, Iñaki Sanz 

Industry Sessions 

Sunday, 12 November 2023 

18:00– 

20:00 

18:00– 

20:00 

Disease Modification: A Roadmap to Slowing 

Organ Damage Progression in Patients with SLE 

Angela Crowley, Ashira Blazer, Rajeev Ragahavn 

Novartis’ Commitment in Rheumatology 

Adam Winseck, Antton Egana, Kelly Montalto 

Monday, 13 November 2023 

18:00– 

20:00 

Expanding Horizons for SLE: An Innovative 

Therapy Option 

Michelle Petri, Richard Furie 

Tuesday, 14 November 2023 

11:30– 

12:15 

18:00– 

20:00 

A Rheumatologist and Nephrologist Discuss 

Kidney Preservation in Lupus Nephritis 

Sheetal Desai, Tina Kochar 

Exploring New Frontiers: CAR T Cell Therapy in 

Autoimmune Diseases 

James Chung, Peter Merkel, Georg Schett, 

Richard Furie, Brad Rovin, Amber Podoll, Peter Maag 

Developed under 

the auspices of 

Supported with educational grants from 

Sponsorship 

received from

Lupus ACR 2023 Brochure LF

Create successful ePaper yourself

Delete template?

Save as template?